Oncology formulation maker Beta Drugs raises Rs.117-Cr from HealthQuad

Panchkula, Haryana-based Beta Drugs , a vertically integrated oncology-focused formulations company, has raised INR 117 crore in primary capital from HealthQuad (via HealthQuad Fund II) and other investors including a Singapore-based investment fund and a private wealth management firm in lieu of a minority stake in the company. The investment will help the drug maker to expand its global reach and operational capabilities.O3 Capital acted as exclusive advisor to Beta Drugs for this transaction. DSK Legal, Universal Legal and Desai & Diwanji were the legal advisors.Beta Drugs claims to have expanded its footprint to over 46 countries, holding accreditations from regulatory bodies such as Brazil and EU. It has a product portfolio across all major oncology segments, including chemotherapy, targeted, hormonal and supportive therapy.